Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis

• DOI: 10.1007/s00296-015-3285-2
• Publication Date: 2015-05-30T06:23:55Z
• Authors: William G. Reiss; Jenny N. Devenport; Jason M. Low; George Wu; Eric H. Sasso
• Keywords: Tocilizumab

The multi-biomarker disease activity (MBDA) score measures 12 proteins involved in the pathophysiology of rheumatoid arthritis (RA) to assess (DA). Previous studies demonstrated correlations between MBDA and clinical DA scores with some RA therapies. In this analysis, relationship changes component biomarkers were evaluated tocilizumab (TCZ)-treated patients. Patients from ACT-RAY study included analysis if they had serum collected at pre-specified time points sufficient for testing ≥1 visit. Descriptive statistics, associations outcomes, percentage agreement categories calculated. Seventy-eight patients similar population. Correlations DAS28-CRP ρ = 0.50 baseline 0.26 week 24. Agreement low/moderate/high was observed 77.1 % 23.7 Mean weeks 4, 12, 24 proportionately smaller than DAS28-CRP. Unlike other biomarkers, interleukin-6 (IL-6) concentrations increased most during TCZ treatment. or CDAI lower versus baseline. magnitude response may be due influence increase IL-6 on score. Thus, obtained treatment should interpreted cautiously context available information.